Related Experiment Video
Updated: Aug 6, 2026
05:33
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
Molecular Engineering of Stimuli-Activatable Protein Degraders for Precise Cancer Therapy
1State Key Laboratory of Chemical Biology & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai201203, China.
Accounts of Chemical Research
|July 17, 2026
Summary
Stimuli-activatable targeted protein degradation (TPD) offers precise cancer therapy by degrading proteins only at tumors. This approach enhances efficacy and minimizes side effects by controlling protein degradation spatiotemporally.
Area of Science:
- Biochemistry
- Oncology
- Nanomedicine
Background:
- Targeted protein degradation (TPD) is a promising cancer therapy, but off-target effects and insufficient drug accumulation limit its clinical use.
- Achieving precise, tumor-specific protein degradation remains a significant challenge in cancer treatment.
Purpose of the Study:
- To review recent advances in designing stimuli-activatable protein degraders for precise cancer therapy.
- To explore the integration of these degraders with nanomedicine platforms for enhanced therapeutic outcomes.
Main Methods:
- Rational design of stimuli-labile prodrugs (e.g., PROTACs) activated by tumor microenvironment cues (acidity, enzymes, heat).
- Development of nanomedicine delivery systems for tumor-specific enrichment of protein degraders.
- Integration of TPD with various cancer therapies (phototherapy, radiotherapy, chemotherapy, immunotherapy).
Main Results:
- Stimuli-activatable protein degraders demonstrate tumor-specific enrichment and controlled degradation of proteins of interest (POIs).
- Nanodegraders targeting tumor acidity and enzymes improve drug distribution and POI degradation.
- Photothermally activatable degraders enable spatiotemporally controlled POI degradation.
- Integration with nanomedicine augments therapeutic outcomes across multiple cancer treatment modalities.
Conclusions:
- Stimuli-activatable TPD, particularly when combined with nanomedicine, offers a powerful strategy for precision cancer therapy.
- Tumor microenvironment-responsive design is crucial for achieving tumor-specific protein degradation and minimizing side effects.
- Further development of these activatable TPD technologies holds significant potential for clinical translation.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:58Regulated Protein Degradation
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...